US Patent

US11939361 — Compositions of peptide inhibitors of Interleukin-23 receptor

Method of Use · Assigned to Janssen Pharmaceutica NV · Expires 2041-11-19 · 16y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compositions of peptide inhibitors of the interleukin-23 receptor for treating autoimmune inflammation and related diseases and disorders.

USPTO Abstract

The present invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4447`	—

Patent Metadata

Patent number: US11939361
Jurisdiction: US
Classification: Method of Use
Expires: 2041-11-19
Drug substance claim: No
Drug product claim: Yes
Assignee: Janssen Pharmaceutica NV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.